Core Insights - Siemens Healthineers reported a strong start to fiscal 2026, confirming its full-year outlook despite facing significant headwinds in diagnostics due to market changes in China [4][13] Imaging Segment - Imaging adjusted EBIT margin was 21.6%, reflecting strong operational margin expansion, with external pressures from tariffs and foreign exchange impacting margins by approximately 200 basis points [1] - Revenue in the imaging segment grew by 5.7% in Q1, driven by photon-counting CT and radiopharmaceuticals, with a comparability change due to an acquisition from Novartis [2] - The combined growth for imaging and precision therapy was around 6%, with a decent equipment book-to-bill ratio of 1.12 [3][5] Diagnostics Segment - Diagnostics revenue fell by about 3% due to volume-based procurement and reimbursement cuts in China, which saw a decline of approximately 5% for the group [5][7] - Outside of China, diagnostics revenues remained stable, with the Americas diagnostic business showing operational growth, particularly from the Atellica franchise, which grew roughly 20% in Q1 [8][10] - Management expects Q2 diagnostics performance to be below the annual growth range due to ongoing challenges in China [14] Financial Performance - The company achieved a group revenue growth of 3.8%, with strong performance in imaging and precision therapy offsetting the decline in diagnostics [10] - Adjusted EPS declined by 3% year-over-year, but excluding the impacts of tariffs and foreign exchange, adjusted EPS would have increased by about 17% [11] - The adjusted EBIT margin for the group was 15%, remaining flat year-over-year, but operationally expanded by 200 basis points when excluding external pressures [10] Tariffs and Foreign Exchange - Tariffs and foreign exchange are expected to be ongoing headwinds throughout fiscal 2026, with quantified impacts of approximately $0.04 from foreign exchange and $0.06 from tariffs in Q1 [12][18] - The company anticipates fully mitigating the impact of tariffs over the next three years, describing them as a temporary drag on margins [12][18] Outlook - Siemens Healthineers confirmed its fiscal 2026 outlook for revenue growth and adjusted EPS, supported by strong performance in imaging and precision therapy [13] - For Q2, the company expects group revenue growth to be below the fiscal 2026 range of 5% to 6%, primarily due to diagnostics challenges in China [14][15]